Several agents that were meant to be used in combination with anti-VEGFs have not met expectations. Though new approaches might still be worth pursuing, proper use of currently available treatments, following validated protocols, should have priority, according to Jordi Monés, MD, PhD.
Perspective: Jordi Monés, MD, PhD
Other Perspective
Managing GA in clinical practice: new challenges, new models
With the new treatments for GA, it is important to re-think the management of patients looking at th
The new era in the management of patients with geographic atrophy
Paolo Lanzetta discusses with Baruch Kuppermann about the new treatments for geographic atrophy appr
Euretina 2023 – Controversies and future trends in intravitreal therapies
IVEG instructional course – Euretina 2023Take-home messagesIn this video, the best of our
Home monitoring
Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r
Related Articles
